Cargando…
Ocular adverse events with immune checkpoint inhibitors
PURPOSE: To quantify the risk of ocular adverse events with immune checkpoint inhibitors (ICIs) as reported to the Food and Drug Administration (FDA). METHODS: Disproportionality analysis using data from U.S. FDA's Adverse Events Reporting System (FAERS) database 2003 to 2018. Data from pharmac...
Autores principales: | Fang, Tony, Maberley, David A., Etminan, Mahyar |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6742617/ https://www.ncbi.nlm.nih.gov/pubmed/31528768 http://dx.doi.org/10.1016/j.joco.2019.05.002 |
Ejemplares similares
-
Ocular adverse events associated with immune checkpoint inhibitors, a scoping review
por: Martens, A., et al.
Publicado: (2023) -
Ocular Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors in Lung Cancer
por: Zhou, Lin, et al.
Publicado: (2021) -
Unexpected Adverse Events of Immune Checkpoint Inhibitors
por: Shalata, Walid, et al.
Publicado: (2023) -
Ocular adverse events associated with immune checkpoint inhibitors: a novel multidisciplinary management algorithm
por: Shahzad, Orthi, et al.
Publicado: (2021) -
Mucocutaneous adverse events to immune checkpoint inhibitors
por: Muhaj, Fiorinda, et al.
Publicado: (2023)